Iovance Biotherapeutics
IOVA
255 hedge funds and large institutions have $379M invested in Iovance Biotherapeutics in 2025 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 92 increasing their positions, 72 reducing their positions, and 84 closing their positions.
40% more call options, than puts
Call options by funds: $3.58M | Put options by funds: $2.55M
28% more repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 72
7.15% less ownership
Funds ownership: 73.13% → 65.97% (-7.2%)
15% less funds holding
Funds holding: 301 → 255 (-46)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
51% less first-time investments, than exits
New positions opened: 41 | Existing positions closed: 84
53% less capital invested
Capital invested by funds: $799M → $379M (-$419M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$22.8M |
| 2 |
MFM
MHR Fund Management
New York
|
+$11.3M |
| 3 |
Two Sigma Investments
New York
|
+$10.5M |
| 4 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
+$6.98M |
| 5 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$6.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$42.3M |
| 2 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
-$30.7M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$16M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$14.7M |
| 5 |
UBS AM
Chicago,
Illinois
|
-$12.7M |
IOVA Hedge Fund Activity: Q2 2025 in Review
255 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q2 2025, worth a combined $379M — down 53% from $799M a quarter earlier.
Sellers outnumbered buyers: 84 funds closed out of IOVA and 41 opened new positions — a net loss of 43 holders — while 72 trimmed existing stakes and 92 added.
The largest buyer was Millennium Management, adding an estimated $22.8M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $42.3M sold.
- 255 institutional investors held Iovance Biotherapeutics (IOVA) as of Q2 2025, down from 301 in Q1 2025.
- Funds reported $379M of Iovance Biotherapeutics stock for Q2 2025, down 53% quarter-over-quarter.
- 41 funds opened new Iovance Biotherapeutics positions in Q2 2025 and 84 closed out, a net change of -43 holders.
- The largest Iovance Biotherapeutics buyer in Q2 2025 was Millennium Management, an estimated $22.8M added.
- The largest Iovance Biotherapeutics seller in Q2 2025 was Perceptive Advisors, an estimated $42.3M sold.
Based on aggregated 13F filings for Q2 2025.